NeoGenomics Inc 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period fromto Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) 33912(Zip Code) (239) 768-0600(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.YesSNo☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YesS No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐NoS As of April24, 2026, the registrant had 130,211,780 shares of common stock, par value $0.001 per share outstanding. TABLE OF CONTENTS PART I FINANCIAL INFORMATIONItem 1. Financial Statements (unaudited)Item 2. Management’s Discussion and Analysis ofFinancial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and Procedures PART II OTHER INFORMATIONItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSIGNATURES FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements generally can be identified by theuse of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intends,” “may,” “plan,” “potential,” , “project,”,“seek,” “will,” “would,” and similar words and expressions, although not all forward-looking statements contain these identifying words. Theseforward-looking statements address various matters, including the Company’s strategy, planned future operations and related expectations withrespect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, the timing,performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospectsand plans, and objectives of management. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involveknown and unknown risks and uncertainties that could cause the Company's actual results, performance or achievements to differ materiallyfrom those expressed or implied by the forward-looking statements. Applicable risks and uncertainties include, among others, the Company'sability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities, to enter new markets andincrease market share in both current and new markets, to assemble and maintain an effective executive team, to continue gaining newcustomers, develop and commercialize new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-rangestrategic priorities, and otherwise implement its business plans, as well as the potential impact of evolving regulatory requirements related tolaboratory developed tests, the impact of tariffs and trade policy uncertainty on the Company's supply chain and costs, and any potentialreimbursement changes by the government and commercial payors, and the risks set forth in Part I, Item 1A, “Risk Factors” in our AnnualReport on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) onFebruary 17, 2026. The for